Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schmitt, Nanni [VerfasserIn]   i
 Jann, Johann-Christoph [VerfasserIn]   i
 Altrock, Eva [VerfasserIn]   i
 Flach, Johanna [VerfasserIn]   i
 Danner, Justine [VerfasserIn]   i
 Uhlig, Stefanie [VerfasserIn]   i
 Streuer, Alexander [VerfasserIn]   i
 Knaflic, Antje [VerfasserIn]   i
 Riabov, Vladimir [VerfasserIn]   i
 Xu, Qingyu [VerfasserIn]   i
 Mehralivand, Arwin [VerfasserIn]   i
 Palme, Iris [VerfasserIn]   i
 Nowak, Verena [VerfasserIn]   i
 Obländer, Julia [VerfasserIn]   i
 Weimer, Nadine [VerfasserIn]   i
 Haselmann, Verena [VerfasserIn]   i
 Jawhar, Ahmed [VerfasserIn]   i
 Darwich, Ali [VerfasserIn]   i
 Weis, Cleo-Aron Thias [VerfasserIn]   i
 Marx, Alexander [VerfasserIn]   i
 Steiner, Laurenz [VerfasserIn]   i
 Jawhar, Mohamad [VerfasserIn]   i
 Metzgeroth, Georgia [VerfasserIn]   i
 Boch, Tobias [VerfasserIn]   i
 Nolte, Florian [VerfasserIn]   i
 Hofmann, Wolf-Karsten [VerfasserIn]   i
 Nowak, Daniel [VerfasserIn]   i
Titel:Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
Verf.angabe:Nanni Schmitt, Johann-Christoph Jann, Eva Altrock, Johanna Flach, Justine Danner, Stefanie Uhlig, Alexander Streuer, Antje Knaflic, Vladimir Riabov, Qingyu Xu, Arwin Mehralivand, Iris Palme, Verena Nowak, Julia Obländer, Nadine Weimer, Verena Haselmann, Ahmed Jawhar, Ali Darwich, Cleo-Aron Weis, Alexander Marx, Laurenz Steiner, Mohamad Jawhar, Georgia Metzgeroth, Tobias Boch, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak
Jahr:2022
Umfang:12 S.
Fussnoten:Online veröffentlicht: 25. Juni 2021 ; Gesehen am 01.06.2023
Titel Quelle:Enthalten in: Leukemia
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2022
Band/Heft Quelle:36(2022), 1, Seite 236-247
ISSN Quelle:1476-5551
Abstract:Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model is applicable as a preclinical platform to address pending clinical questions by interrogating the efficacy and safety of the thrombopoietin receptor agonist eltrombopag. Our preclinical study included n = 49 xenografts generated from n = 9 MDS patient samples. Substance efficacy was evidenced by FACS-based human platelet quantification and clonal bone marrow evolution was reconstructed by serial whole-exome sequencing of the PDX samples. In contrast to clinical trials in humans, this experimental setup allowed vehicle- and replicate-controlled analyses on a patient-individual level deciphering substance-specific effects from natural disease progression. We found that eltrombopag effectively stimulated thrombopoiesis in MDS PDX without adversely affecting the patients’ clonal composition. In conclusion, our MDS PDX model is a useful tool for testing new therapeutic concepts in MDS preceding clinical trials.
DOI:doi:10.1038/s41375-021-01327-w
URL:kostenfrei: Volltext: https://doi.org/10.1038/s41375-021-01327-w
 kostenfrei: Volltext: https://www.nature.com/articles/s41375-021-01327-w
 DOI: https://doi.org/10.1038/s41375-021-01327-w
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cancer models
 Myelodysplastic syndrome
 Preclinical research
K10plus-PPN:1847147666
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69081532   QR-Code
zum Seitenanfang